Adocia SA · EURONEXT:ADOC
Adocia SA — Investor Presentation (January 2020)
32 slides from Adocia SA's investor presentation, January 2020

Slide 1: Adocia Corporate Presentation January 2020
ADOCIA CORPORATE PRESENTATION January 2020

Slide 2: Disclaimer
DISCLAIMER This corporate presentation (the “Presentation”) has been prepared by ADOCIA (the “Company”) and is provided for information purposes only. It is not for promotional use. References herein to the Presentation shall mean and include this document, any oral presentation accompanying this do

Slide 3: Adocia in Summary
ADOCIA IN SUMMARY 1 2 3 4 5 Business model Clinical & $135M Licensing Global insulin Expansion to based on preclinical agreement ($50M supply adjacent innovative pipeline includes upfront) signed in agreement with indications formulation competitive 2018 with Tonghua THDB secures (Obesity, aiming to

Slide 4: Delivering Personalized Treatments for People with Diabetes
DELIVERING PERSONALIZED TREATMENTS FOR PEOPLE WITH DIABETES

Slide 5: People with Diabetes Require More Personalized and More Physiologic Treatments
PEOPLE WITH DIABETES REQUIRE MORE PERSONALIZED AND MORE PHYSIOLOGIC TREATMENTS 425M1 people with Despite 100 years of medical treatment, long-term consequences of diabetes diabetes in 2017 26M2 remain a major issue. on insulin 79%3 live with severe 1 International Diabetes Federation Atlas, 2017 com

Slide 6: People with Diabetes Have Different Profiles and Different Needs
PEOPLE WITH DIABETES HAVE DIFFERENT PROFILES AND DIFFERENT NEEDS « Diabetes » covers two types of disease, at different stages, with a range of complications, 90% T2D requiring a variety of treatments (10% T1D) Diabetes care is evolving towards more 65%1 drug/device integration and more diverse of U

Slide 7: Adocia: Innovative Single & Bi-Hormonal Coformulations
ADOCIA : INNOVATIVE SINGLE & BI-HORMONAL COFORMULATIONS FOR PERSONALIZED CARE OF DIABETES AND OBESITY Diabetes BC LISPRO & BC COMBO Adocia is committed to developing more efficient, easy-to-use treatments addressing the underlying complexity of diabetes Diabetes M1 PRAM ▪ Biobetters leveraging estab

Slide 8: Differentiated Pipeline of Biobetters & Bi-Hormonal Formulations
DIFFERENTIATED PIPELINE OF BIOBETTERS & BI-HORMONAL FORMULATIONS FOR THE TREATMENT OF DIABETES & METABOLIC DISEASES Preclinics Phase Phase Phase P C 1 2 3 BIOBETTERS BC Lispro U100 Diabetes BC Lispro U200 Diabetes BC Combo U200 Diabetes BC Glucagon Hypoglycemia BI-HORMONAL FORMULATIONS M1 PRAM Diabe

Slide 9: Biobetters: BC Lispro, BC Combo, BC Glucagon
BIOBETTERS: BC LISPRO, BC COMBO, BC GLUCAGON UNLOCKING THE POTENTIAL OF DIABETES TREATMENTS THROUGH SMART FORMULATION

Slide 10: BioChaperone Lispro: Ultra-Rapid Insulin
BIOCHAPERONE LISPRO ULTRA-RAPID INSULIN FOR TIGHTER POSTPRANDIAL GLYCEMIC CONTROL Post-meal glycaemia in T1D 9 trials in >250 people with T1D & T2D vs. Novolog, Humalog & Fiasp: ▪ Strong post-prandial glucose control AUC0-2h: ▪ Profile enabling dose-timing flexibility -61%* ▪ Potential for lower hyp

Slide 11: BioChaperone Lispro
BIOCHAPERONE LISPRO KEY ELEMENT TO ACHIEVE OPTIMIZED PERSONALIZED CARE IN DIABETES BioChaperone Lispro offers 3 key differentiating attributes: ▪ Dose timing flexibility in pens $7B ▪ Potential for high performance in Prandial insulin automated delivery systems market (2016)1 ▪ Concentrated U200 for

Slide 12: BioChaperone Lispro: Next Steps for Worldwide Development
BIOCHAPERONE LISPRO NEXT STEPS FOR WORLDWIDE DEVELOPMENT CHINA US/EU/Japan/RoW Partnered to Tonghua Dongbao Seeking partners on these territories Phase 3 start targeted 2020 Bridging study planned H1 2020 ▪ Milestone attached ▪ Comparability study BC Lispro (THDB insulin lispro) vs. BC Lispro (Humal

Slide 13: BioChaperone Combo U200 (Glargine / Lispro)
BIOCHAPERONE COMBO U200 (GLARGINE / LISPRO) SAFER AND MORE EFFICIENT ALTERNATIVE TO PREMIX INSULIN Premix is used: BC Combo U200 presents: ▪ As 1st line insulin treatment in ▪ Stronger postprandial control and China lower risk of hypoglycemia vs. ▪ By elderly and T2D patients in Humalog® Mix25 in pe

Slide 14: BioChaperone Glucagon
BIOCHAPERONE GLUCAGON READY-TO-USE SOLUTION FOR RESCUE FROM SEVERE HYPOGLYCEMIA 35%1 Plasma glucose Annual prevalence In a Phase 1 study in people with of severe hypo in T1D3, BC Glucagon (1mg) for rescue: T1D patients ▪ Was safe and well tolerated BioChaperone® Glucagon is a ready- ▪ Efficiently re

Slide 15: Advanced Bi-Hormonal Coformulations
ADVANCED BI-HORMONAL COFORMULATIONS DELIVERING GROUNDBREAKING OUTCOMES FOR PEOPLE WITH DIABETES

Slide 16: Amylin: The Case of the Missing Hormone
AMYLIN THE CASE OF THE MISSING HORMONE In non-diabetic people, a time-sensitive hormonal pattern maintains normoglycemia. Prandial control involves both insulin and amylin. ADDING AMYLIN IN TANDEM WITH INSULIN IS KEY TO IMPROVING GLYCEMIC CONTROL AND OTHER METABOLIC AND NON-METABOLIC EFFECTS CORPORA

Slide 17: M1 Pram: Coformulation of Insulin with Pramlintide
M1 PRAM COFORMULATION OF INSULIN WITH PRAMLINTIDE (AMYLIN ANALOG ) Activates amylin receptors in different brain areas Unique Amylin multiple functions cannot ▪ Satiety be restored by algorithms driving ▪ Well-being automated insulin delivery systems ▪ Protects cognitive M1 PRAM combines prandial in

Slide 18: M1 Pram: Next Generation Prandial Treatment
M1 PRAM NEXT GENERATION PRANDIAL TREATMENT FOR HOLISTIC EFFECTS M1 PRAM leverages pramlintide’s In a study in 24 people with T1D1 demonstrated clinical benefits M1 PRAM (at mealtime) showed: « This combination has the ▪ 85% decrease in glycemic potential to finally deliver excursion in the first 2 h

Slide 19: M1 Pram: Potential for Neuroprotective Effects
M1 PRAM POTENTIAL FOR NEUROPROTECTIVE EFFECTS IN T1D AND T2D Pramlintide’s use is associated with positive central nervous system effects ▪ Satiety 21%1 Of T1D ▪ “Well-being”2 27%1 Of T2D ▪ Alzheimer’s disease (AD) is correlated with report 70%3 accumulation of amyloid plaques and depressive Of T2D

Slide 20: BioChaperone Glucagon GLP-1 Coformulation
BIOCHAPERONE GLUCAGON GLP-1 COFORMULATION NEW GENERATION OF TREATMENT FOR DIABETES AND OBESITY Obesity is a key concern in the general population and for people with diabetes Body weight reduction 36.5%1 (14-day study in n=10 DIO mice) US adults Based on BC Glucagon, Adocia develops an are obese inj

Slide 21: Chinese Partnership Supports Adocia Growth
CHINESE PARTNERSHIP SUPPORTS ADOCIA GROWTH LICENSING & SUPPLY AGREEMENTS WITH TONGHUA DONGBAO

Slide 22: China Is "The Place to Be"
CHINA IS « THE PLACE TO BE »… ESPECIALLY IN DIABETES The Chinese insulin market is vast and remains 1.4 underserved. Its growth is driven by multiple factors: ▪ Better diagnosis billion Chinese ▪ Better reimbursement population 2018 10.9% ▪ Increasing medical access to remote areas Diabetes 65% prev

Slide 23: Tonghua Dongbao Is the Right Partner
… AND TONGHUA DONGBAO IS THE RIGHT PARTNER $4.4 Bn Market cap (Nov 2019) 25%1 YOY revenue growth 26%2 Share of Chinese human insulin 78%1 market Of revenue from insulin 1 Data THDB 2 IQVIA, volume, 2018 CORPORATE PRESENTATION – JANUARY 2020 • 23

Slide 24: Adocia and THDB Entered Strategic Alliance
ADOCIA AND THDB ENTERED STRATEGIC ALLIANCE TO DEVELOP BEST-IN-CLASS INSULINS In April 2018, Adocia and Tonghua Dongbao announced a strategic partnership to develop and $50M +$85M commercialize BC Combo & BC Lispro in China and Upfront (development other Asian and Middle East territories milestones)

Slide 25: Strategic Supply Agreements with Tonghua Dongbao
STRATEGIC SUPPLY AGREEMENTS WITH TONGHUA DONGBAO OPEN GLOBAL OPPORTUNITIES FOR ADOCIA With access to stable, high-quality insulin lispro and insulin glargine supply, Adocia can out-license and commercialize BC Lispro and BC Combo, notably in the US, EU and Japan Partnering opportunities are multipli

Slide 26: Financial Overview
FINANCIAL OVERVIEW ADOCIA innovative medicine for everyone, everywhere

Slide 27: Key Financial Elements
KEY FINANCIAL ELEMENTS Financial Summary Shareholders’ equity (Dec 2019) Analysts Kepler Market Listed on Euronext Paris (ADOC) Free Float Soula Family 22,1 % Arsène Guekam 59.1% ▪ 6.9M shares outstanding Oddo ▪ ADR program in the US (ADOCY) Oussama Denguir €85M raised since inception HC Wainwright

Slide 28: Expected Newsflow
EXPECTED NEWSFLOW ADOCIA innovative medicine for everyone, everywhere

Slide 29: Upcoming Newsflow
UPCOMING NEWSFLOW MULTIPLE MILESTONES EXPECTED IN 2020 BI-HORMONAL BIOBETTERS BUSINESS COFORMULATIONS BC LISPRO M1PRAM BC LISPRO & BC COMBO ▪ China (THDB): Phase 3 start expected ▪ Results from second Phase 1/2 trial ▪ Looking to partner in in 2020 expected Q1 2020 US/EU/Japan/LatAm/Oceania ▪ US/EU/

Slide 30: Conclusion
CONCLUSION 1 CHINA: A TARGET MARKET Strategic partnership with Tonghua Dongbao opens Chinese and international markets 2 A PIPELINE AT THE FOREFRONT OF DIABETES AND METABOLIC DISEASE CHALLENGES BC Lispro displays a very promising profile in the context of personalized and integrated diabetes care (p

Slide 31: Notes
NOTES CORPORATE PRESENTATION – JANUARY 2020 • 31

Slide 32: Thank You for Your Kind Interest
THANK YOU FOR YOUR KIND INTEREST ADOCIA 115 avenue Lacassagne 69003 Lyon – France Tel +33 4 72 610 610 contact@adocia.com
Source: Internet Archive copy of adocia.com
More decks from Adocia SA
Q3 2026 Earnings Presentation19 slides · Nov 2, 2026
Investor Presentation (November 2026)33 slides · November 2026
Investor Presentation (June 2026)43 slides · June 2026
Investor Presentation (March 2026)43 slides · March 2026
Investor Presentation (November 2025)42 slides · November 2025
Shareholder Meeting (June 2025)85 slides · Jun 11, 2025